Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New heart device enables simultaneous implantation of an aortic tissue valve and ascending aorta

Sorin : 08 November, 2012  (New Product)
Sorin Group launching the Mitroflow Valsalva Conduit in the USA, which claims to be the only Valsalva conduit graft approved by the US Food and Drug Administration (FDA) for use in combination with an aortic tissue valve.


Previously available only with mechanical valves, Sorin Group's innovative Mitroflow Valsalva Conduit now offers cardiac surgeons a solution for replacing simultaneously the ascending aorta and the diseased aortic valve with Sorin’s highly durable Mitroflow pericardial aortic valve.



The Mitroflow Aortic Pericardial Heart Valve has consistently demonstrated excellent hemodynamic performance, ease of implant and proven durability. Introduced in Europe in 1982 and US FDA cleared in 2007, the Mitroflow valve is supported by 21 years of published long-term durability and demonstrates outstanding performance in patients under 60 years of age (Refs 1, 2).



In addition to limiting the bypass, cross-clamp and procedural time, and reducing potential risks for the patient, the Mitroflow Valsalva Conduit also replicates the native sinus thereby preserving the patient's physiological haemodynamics and obviating the need for lifelong anticoagulation treatment. The Mitroflow Valsalva Conduit graft is impregnated with absorbable bovine cross-linked gelatine, thus eliminating the need for preclotting.



"The Mitroflow Valsalva Conduit offers the surgeons a convenient way to connect the Mitroflow valve to a clinically proven aortic graft at point of use in the operating room, allowing a quick and effective assembly of the Mitroflow valve," said Wilson Szeto, MD, Associate Professor of Cardiac Surgery, University of Pennsylvania Medical Center, Penn Presbytarian Medical Center.



"The Mitroflow Valsalva Conduit launch represents our continued commitment to innovation and enhances our tissue heart valve portfolio in the US," said Andre-Michel Ballester, Chief Executive Officer, Sorin Group.



Ref 1: Yankah, et al. Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years. J Thorac Cardiovasc Surg. 2008;136:688-696.



Ref 2: Yankah, C Mitroflow pericardial aortic bioprosthesis in patients younger than 60 years. J Thorac Cardiovasc Surg. 2010;140: e83-4.6.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo